1. Scrip
  2. >>Business

Meek To Drive M&A At Ipsen, Building On Two Major Launches

 
• By John Davis

France’s Ipsen is preparing to launch Cabometyx in Europe this autumn and telotristat next year, and the business development expertise of its new CEO will be useful in replenishing its product portfolio.

David Meek only started work as CEO of France’s mid-sized pharmaceutical company, Ipsen, a couple of weeks ago, but he has already seen his new company gain a positive opinion from Europe’s CHMP for a new cancer product, and the presentation of positive earnings results for the second quarter of 2016.

“I couldn’t ask for a better first 10 days,” he told analysts during a July 28 review of the company’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins

 
• By Mandy Jackson

Public Company Edition: Public company funding in 2025 is down from 2024, but after recent positive data readouts Vera accessed up to $450m in new debt, while Taysha and Trevi grossed $200m and $100m, respectively, in stock offerings. Meanwhile, Keros, Stealth and others cut jobs.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

 
• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Europe’s Drugmakers Lament EU Pharma Package

 
• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

 
• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

More from Scrip

Europe’s Drugmakers Lament EU Pharma Package

 
• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

 
• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.